Fast Market Research recommends "Epidermolysis Bullosa - Pipeline Review, H2 2012" from Global Markets Direct, now available

Boston, MA -- (SBWire) -- 12/05/2012 --Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Epidermolysis Bullosa - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epidermolysis Bullosa.
- A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Epidermolysis Bullosa pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Epidermolysis Bullosa - Pipeline Review, H1 2012
- Epidermolysis Bullosa - Pipeline Review, H2 2011
- Obesity - Pipeline Review, H2 2012
- Astrocytoma - Pipeline Review, H2 2012
- Lymphoma - Pipeline Review, H2 2012
- Chemotherapy Effects - Pipeline Review, H2 2012
- Schizophrenia - Pipeline Review, H2 2012
- Neuropathic Pain - Pipeline Review, H2 2012
- Myelodysplastic Syndrome - Pipeline Review, H2 2012
- Autoimmune Disorders - Pipeline Review, H2 2012